CPVT is related to an RyR2 mutation which is a calcium channel. Flecainide is a type 1c antiarrhythmic which acts on the sodium channel. There is controversy as to how this is of benefit but it is clear from clinical studies that flecainide can reduce both atrial and ventricular arrhythmias in CPVT. What is the mechanism and what is the evidence for this?